| scholarly article | Q13442814 |
| review article | Q7318358 |
| P50 | author | Steve Steinhubl | Q57450607 |
| Paul A Gurbel | Q89230591 | ||
| P2093 | author name string | Kenneth G Mann | |
| Alan D Michelson | |||
| Richard C Becker | |||
| P433 | issue | 19 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1822-1834 | |
| P577 | publication date | 2007-10-23 | |
| P1433 | published in | Journal of the American College of Cardiology | Q2984355 |
| P1476 | title | Platelet function monitoring in patients with coronary artery disease | |
| P478 | volume | 50 |
| Q36836461 | A Chinese Immigrant Paradox? Low Coronary Heart Disease Incidence but Higher Short-Term Mortality in Western-Dwelling Chinese Immigrants: A Systematic Review and Meta-Analysis. |
| Q37550156 | A clinician's perspective of emerging P2Y(12)-directed pharmacotherapies, ex vivo measurement tools, and clinical outcomes |
| Q52675556 | ADP Platelet Hyperreactivity Predicts Cardiovascular Disease in the FHS (Framingham Heart Study). |
| Q43736778 | Abciximab bolus with optional infusion in intervention for ST-elevation myocardial infarction |
| Q34111144 | Adenosine diphosphate–induced platelet-fibrin clot strength: A new thrombelastographic indicator of long-term poststenting ischemic events |
| Q38027576 | Advances in platelet function testing assessing bleeding complications in patients with coronary artery disease |
| Q36087455 | An Assay of Measuring Platelet Reactivity Using Monoclonal Antibody against Activated Platelet Glycoprotein IIb/IIIa in Patients Taking Clopidogrel |
| Q37437158 | Antiplatelet drug 'resistance'. Part 1: mechanisms and clinical measurements |
| Q52903388 | Antiplatelet effects of clopidogrel and aspirin after interventional patent foramen ovale/ atrium septum defect closure. |
| Q37313410 | Antithrombotic therapies in primary angioplasty: rationale, results and future directions |
| Q35660184 | Antithrombotic therapy in patients with acute coronary syndromes: a balance between protection from ischemic events and risk of bleeding. |
| Q38715643 | Antithrombotic therapy in peripheral artery disease |
| Q37798798 | Aspirin and antiplatelet agent resistance: implications for prevention of secondary stroke. |
| Q37458916 | Aspirin and clopidogrel hyporesponsiveness and nonresponsiveness in patients with coronary artery stenting |
| Q34389630 | Aspirin resistance: Fact or fiction? A point of view |
| Q37164379 | Assessing the current role of platelet function testing. |
| Q37248584 | Assessment of aspirin resistance varies on a temporal basis in patients with ischaemic heart disease |
| Q37902507 | Assessment of oral antithrombotic therapy by platelet function testing |
| Q36720281 | Association between insulin receptor substrate-1 polymorphisms and high platelet reactivity with clopidogrel therapy in coronary artery disease patients with type 2 diabetes mellitus |
| Q39204219 | Biobanks for cardiovascular epidemiology and prevention |
| Q34906975 | Bivalirudin is a dual inhibitor of thrombin and collagen-dependent platelet activation in patients undergoing percutaneous coronary intervention |
| Q44906555 | CYP2C19 genotypes and their impact on clopidogrel responsiveness in percutaneous coronary intervention |
| Q36477309 | CYP2C19*2 and Other Allelic Variants Affecting Platelet Response to Clopidogrel Tested by Thrombelastography in Patients with Acute Coronary Syndrome |
| Q38003373 | Cardiovascular devices and platelet interactions: understanding the role of injury, flow, and cellular responses |
| Q89751378 | Clinical Implications of "Tailored" Antiplatelet Therapy in Patients With Chronic Total Occlusion |
| Q36800844 | Clinical characteristics associated with high on-treatment platelet reactivity of patients undergoing PCI after a 300 mg loading dose of clopidogrel, measured by thrombelastography |
| Q38016848 | Clinical pharmacogenomics of warfarin and clopidogrel |
| Q38307535 | Clinical pharmacokinetics and pharmacodynamics of clopidogrel |
| Q37591007 | Clinical pharmacology of antithrombotic drugs in coronary artery disease |
| Q35048059 | Clinical, pharmacokinetic, and pharmacogenetic determinants of clopidogrel resistance in Korean patients with acute coronary syndrome |
| Q38640902 | Clopidogrel Response Variability: Review of the Literature and Practical Considerations |
| Q37627874 | Clopidogrel pharmacogenomics and risk of inadequate platelet inhibition: US FDA recommendations |
| Q36804776 | Comparing of light transmittance aggregometry and modified thrombelastograph in predicting clinical outcomes in Chinese patients undergoing coronary stenting with clopidogrel |
| Q85194020 | Comparison of Two Platelet Activation Markers Using Flow Cytometry After In Vitro Shear Stress Exposure of Whole Human Blood |
| Q42055431 | Comparison of VerifyNow-P2Y12 test and Flow Cytometry for monitoring individual platelet response to clopidogrel. What is the cut-off value for identifying patients who are low responders to clopidogrel therapy? |
| Q38122999 | Comparison of on-treatment platelet reactivity between triple antiplatelet therapy with cilostazol and standard dual antiplatelet therapy in patients undergoing coronary interventions: a meta-analysis |
| Q26829251 | Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding |
| Q37781893 | Controversies in Oral Antiplatelet Therapy in Patients Undergoing Aortocoronary Bypass Surgery |
| Q53471405 | Correlation of high post-treatment platelet reactivity assessed by light transmittance aggregometry and the VerifyNow P2Y12 assay. |
| Q37605071 | Decreased platelet responsiveness to clopidogrel correlates with CYP2C19 and PON1 polymorphisms in atherosclerotic patients |
| Q53131906 | Depression and coronary heart disease. |
| Q35033557 | Detection of clopidogrel hyporesponsiveness using a point-of-care assay and the impact of additional cilostazol administration after coronary stent implantation in diabetic patients |
| Q38347336 | Developments in Oral Antiplatelet Agents for the Treatment of Acute Coronary Syndromes: Clopidogrel, Prasugrel, and Ticagrelor |
| Q91846403 | Diabetes and Platelet Response to Low-Dose Aspirin |
| Q33397223 | Differences in platelet function in patients with acute myeloid leukemia and myelodysplasia compared to equally thrombocytopenic patients with immune thrombocytopenia. |
| Q33602359 | Differences in thrombus structure and kinetics in patients with type 2 diabetes mellitus after non ST elevation acute coronary syndrome |
| Q53833189 | Distribution of ABCB1, CYP3A5, CYP2C19, and P2RY12 gene polymorphisms in a Mexican Mestizos population. |
| Q37697780 | Drug interaction between clopidogrel and proton pump inhibitors |
| Q45797863 | Effect of different anticoagulants on multiple electrode platelet aggregometry after clopidogrel and aspirin administration in patients undergoing coronary stent implantation: a comparison between citrate and hirudin |
| Q57367552 | Effects of thermosensitive poly(N-isopropylacrylamide) on blood coagulation |
| Q84569733 | Evaluation of the platelet function analyzer (PFA-100) vs. the thromboelastogram (TEG) in the clinical setting |
| Q37988850 | Evolving role of platelet function testing in coronary artery interventions |
| Q38243032 | Expert consensus document: World Heart Federation expert consensus statement on antiplatelet therapy in East Asian patients with ACS or undergoing PCI. |
| Q37709405 | Factors associated with clopidogrel nonresponsiveness |
| Q37991382 | Genetic and non-genetic factors affecting the response to clopidogrel therapy. |
| Q37697779 | Genetic causes of clopidogrel nonresponsiveness: which ones really count? |
| Q38056525 | Genetic polymorphisms and drug interactions leading to clopidogrel resistance: why the Asian population requires special attention. |
| Q38262149 | Genotype- and phenotype-directed antiplatelet therapy selection in patients with acute coronary syndromes |
| Q37907918 | Genotypic and phenotypic assessment of platelet function and response to P2Y12 antagonists |
| Q37942701 | Glycoprotein IIb-IIIa inhibitors |
| Q30450312 | High platelet reactivity on clopidogrel therapy correlates with increased coronary atherosclerosis and calcification: a volumetric intravascular ultrasound study |
| Q49132617 | High residual platelet reactivity (HRPR) for adenosine diphosphate (ADP) stimuli is a determinant factor for long-term outcomes in acute ischemic stroke with anti-platelet agents: The meaning of HRPR after ADP might be more prominent in large athero |
| Q51035409 | Highlights from the III International Symposium of Thrombosis and Anticoagulation (ISTA), October 14-16, 2010, São Paulo, Brazil. |
| Q50956895 | Highlights from the IV International Symposium of Thrombosis and Anticoagulation (ISTA), October 20-21, 2011, Salvador, Bahia, Brazil. |
| Q34211191 | Hostility and platelet reactivity in individuals without a history of cardiovascular disease events |
| Q51290210 | Hyperreactive platelet phenotypes: relationship to altered serotonin transporter number, transport kinetics and intrinsic response to adrenergic co-stimulation. |
| Q37203987 | Impact of Cytochrome P450 2C19*2 and *3 on Clopidogrel Loading Dose in Saudi Patients with Acute Coronary Syndrome |
| Q41023511 | Impact of non-inhibited platelet supplementation on platelet reactivity in patients treated with prasugrel or ticagrelor for an acute coronary syndrome: An ex vivo study |
| Q50935485 | In vitro shear stress-induced platelet activation: sensitivity of human and bovine blood. |
| Q45956876 | Influence of statin treatment on platelet inhibition by clopidogrel - a randomized comparison of rosuvastatin, atorvastatin and simvastatin co-treatment. |
| Q57212706 | Is a high maintenance dose of clopidogrel suitable for overcoming clopidogrel resistance in patients? |
| Q38012079 | Latest evidence in personalized antiplatelet therapy in patients with acute coronary syndromes undergoing percutaneous coronary intervention |
| Q37638183 | Management of platelet-directed pharmacotherapy in patients with atherosclerotic coronary artery disease undergoing elective endoscopic gastrointestinal procedures |
| Q37084956 | Mean platelet volume and prevalence of peripheral artery disease, the National Health and Nutrition Examination Survey, 1999–2004 |
| Q37127450 | Mean platelet volume as a predictor of cardiovascular risk: a systematic review and meta-analysis. |
| Q37257153 | Mean platelet volume reproducibility and association with platelet activity and anti-platelet therapy. |
| Q43704129 | Measurement of platelet P-selectin for remote testing of platelet function during treatment with clopidogrel and/or aspirin |
| Q37362783 | Monitoring oral antiplatelet therapy: is it justified? |
| Q35373683 | Monitoring the effectiveness of antiplatelet therapy: opportunities and limitations |
| Q47709533 | More, More, More: Reducing Thrombosis in Acute Coronary Syndromes Beyond Dual Antiplatelet Therapy-Current Data and Future Directions |
| Q42461765 | Nephropathy in type 1 diabetes is associated with increased circulating activated platelets and platelet hyperreactivity |
| Q42090585 | No effect of clopidogrel activity or cessation on vascular function or markers of inflammation |
| Q37958763 | Novel antiplatelet therapies |
| Q37762149 | Overcoming 'resistance' to antiplatelet therapy: targeting the issue of nonadherence |
| Q47835449 | PIK3CG single nucleotide polymorphisms are associated with poor responsiveness to clopidogrel and increased risk of ischemia in patients with coronary heart disease. |
| Q82951856 | Paraoxonase-1 is a major determinant of clopidogrel efficacy |
| Q47554146 | Peripheral blood gene expression signatures which reflect smoking and aspirin exposure are associated with cardiovascular events |
| Q37642822 | Personalized antiplatelet therapy for coronary artery disease patients: is this the future? |
| Q38156786 | Personalized antiplatelet therapy: state of the art. |
| Q38100809 | Personalized diagnostics and biosensors: a review of the biology and technology needed for personalized medicine |
| Q47130405 | Pharmacogenetics in Cardiovascular Medicine |
| Q38116753 | Pharmacogenomics of anti-platelet and anti-coagulation therapy |
| Q27022443 | Pharmacogenomics of anti-platelet therapy: how much evidence is enough for clinical implementation? |
| Q38101963 | Pharmacotherapy for the reduction of stent thrombosis |
| Q37579228 | Platelet P2Y12 receptor inhibition by thienopyridines: status and future |
| Q51328676 | Platelet RNA as a novel biomarker for the response to antiplatelet therapy. |
| Q33896059 | Platelet activity and cardiovascular risk in apparently healthy individuals: a review of the data |
| Q35245686 | Platelet aggregation and mental stress induced myocardial ischemia: Results from the Responses of Myocardial Ischemia to Escitalopram Treatment (REMIT) study |
| Q38007894 | Platelet function and inhibition in ischemic heart disease |
| Q38930441 | Platelet function testing in cardiac surgery |
| Q51746988 | Platelet function testing in contemporary clinical and interventional practice. |
| Q38089082 | Platelet function tests for the monitoring of P2Y12 inhibitors |
| Q44621004 | Platelet function: new drugs, new assays : possible impacts on operative medicine? |
| Q53130046 | Platelet reactivity and clinical outcomes in patients using CYP3A4-metabolized statins with clopidogrel in percutaneous coronary intervention. |
| Q41517183 | Platelet reactivity in MitraClip patients |
| Q50140654 | Platelet reactivity-adjusted antiplatelet therapy in patients with percutaneous coronary intervention: a meta-analysis of randomized controlled trials |
| Q27010236 | Platelet-reactivity tests identify patients at risk of secondary cardiovascular events: a systematic review and meta-analysis |
| Q37196840 | Platelets: developmental biology, physiology, and translatable platforms for preclinical investigation and drug development. |
| Q37516723 | Point-of-care assessment of platelet reactivity in the emergency department may facilitate rapid rule-out of acute coronary syndromes: a prospective cohort pilot feasibility study |
| Q46202600 | Population pharmacokinetic/pharmacodynamic modeling of clopidogrel in Korean healthy volunteers and stroke patients. |
| Q54384410 | Prevalence of CYP2C19 polymorphisms in the Lebanese population. |
| Q38543311 | Proteomic signatures of antiplatelet drugs: new approaches to exploring drug effects. |
| Q34186272 | Racial differences in resistance to P2Y12 receptor antagonists in type 2 diabetic subjects |
| Q37540088 | Recent developments in clopidogrel pharmacology and their relation to clinical outcomes |
| Q37625872 | Reduced platelet hyper-reactivity and platelet-leukocyte aggregation after periodontal therapy |
| Q34624862 | Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis |
| Q55405593 | Relationship between high platelet reactivity on clopidogrel and long-term clinical outcomes after drug-eluting stents implantation (PAINT-DES): a prospective, propensity score-matched cohort study. |
| Q33740877 | Relationship between monocyte-platelet aggregation and endothelial function in middle-aged and elderly adults |
| Q44747491 | Relationship between platelet volume indices with macrovascular and peripheral neuropathy complications in type 2 diabetic patients |
| Q57764181 | Residual platelet reactivity to predict long-term clinical outcomes after clopidogrel loading in patients with acute coronary syndromes: comparison of different cutoff values by light transmission aggregometry from the responsiveness to clopidogrel a |
| Q38258270 | Resistance to antiplatelet drugs: what progress has been made? |
| Q42533914 | Responding to the clopidogrel warning by the US food and drug administration: real life is complicated |
| Q40689554 | Safety and efficacy of policosanol in patients with high on-treatment platelet reactivity after drug-eluting stent implantation: two-year follow-up results |
| Q40010554 | Selecting optimal antiplatelet therapy based on platelet function monitoring in patients with coronary artery disease |
| Q45381763 | Sequential ADP-stimulated light transmission and multiple electrode aggregometry in patients taking aspirin and clopidogrel after non ST-elevation myocardial infarction |
| Q90181215 | Sex Differences in Circulating Biomarkers of Cardiovascular Disease |
| Q39809514 | Significant increase in clopidogrel use across U.S. children's hospitals |
| Q38412151 | Similar Impact of Clopidogrel or Ticagrelor on Carotid Atherosclerotic Plaque Inflammation. |
| Q30373414 | State-of-the-Art: Hypo-responsiveness to oral antiplatelet therapy in patients with type 2 diabetes mellitus. |
| Q48923498 | Strategy for the hemocompatibility testing of microparticles |
| Q92075011 | Stratified Approaches to Antiplatelet Therapies Based on Platelet Reactivity Testing |
| Q50449062 | Sulfasalazine and its metabolites inhibit platelet function in patients with inflammatory arthritis. |
| Q45921699 | The antiplatelet effect of atorvastatin in patients with acute coronary syndrome depends on the hs-CRP level. |
| Q39704629 | The concordance and correlation of measurements by multiple electrode and light transmittance aggregometries based on the pre-defined cutoffs of high and low on-treatment platelet reactivity |
| Q33893919 | The impact of generic clopidogrel bisulfate on platelet inhibition in patients with coronary artery stents: results of the ACCEL-GENERIC study |
| Q33479327 | The impact of platelet function or C-reactive protein, on cardiovascular events after an acute myocardial infarction |
| Q51063040 | The net clinical benefit of personalized antiplatelet therapy in patients undergoing percutaneous coronary intervention. |
| Q37315628 | The use of the VerifyNow system to monitor antiplatelet therapy: a review of the current evidence |
| Q43612447 | Thresholds for platelet reactivity to predict clinical events after coronary intervention are different in patients with and without diabetes mellitus |
| Q36589808 | Thromboelastography for monitoring platelet function in unruptured intracranial aneurysm patients undergoing stent placement |
| Q35916268 | Time-dependent changes in non-COX-1-dependent platelet function with daily aspirin therapy |
| Q38020983 | Treatment of inherited platelet disorders |
| Q37936014 | Variability of clopidogrel response in patients with type 2 diabetes mellitus |
| Q43970520 | Vascular and platelet responses to aspirin in patients with coronary artery disease |
| Q37704842 | What is the risk of intensifying platelet inhibition beyond clopidogrel? A systematic review and a critical appraisal of the role of prasugrel |
Search more.